Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: A prospective, randomized controlled study

World Journal of Urology

Volumn 28, Issue 4, 2010, Pages 413-418

  Saika, Takashi ^a   Tsushima, Tomoyasu ^b   Nasu, Yasutomo ^a   Miyaji, Yoshiyuki ^c   Saegusa, Michihisa ^d   Takeda, Katsuji ^e   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^c Iwakuni Medical Center   (Japan)

^d HIROSHIMA CITY HOSPITAL   (Japan)

^e KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Administration; Bladder; Bladder neoplasms; Epirubicin; Intravesical; Local; Neoplasm recurrence

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; EPIRUBICIN;

AGED; ARTICLE; BLADDER TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR RECURRENCE; UROLOGIC SURGERY; CARCINOMA, TRANSITIONAL CELL; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 77954864870     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0502-1     Document Type: Article

References (18)

1. Witjes JA (2009) Topic issue on new treatments in bladder cancer. World J Urol 27: 285-287.
2. Lamm DL, Blumenstein BA, Crawford ED et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209.
3. Witjes JA, Meijden AP, Sylvester LC et al (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52: 403-410.
4. Okamura K, Ono Y, Kinukawa T et al (2002) Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94: 2363-2368.
5. Witjes JA, Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53: 45-52.
6. Hinotsu S, Akaza H, Isaka S et al (2002) Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer. Fifth Study of the Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Gan To Kagaku Ryoho 29: 73-80.
7. Ali-el-Dein B, Nabeeh A, el-Baz M et al (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79: 731-735.
8. Melekos MD, Dauaher H, Fokaefs E, Barbalias G (1992) Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol 147: 371-375.
9. Oosterlinck W, Kurth KH, Schröder F et al (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749-752.
10. Gudjónsson S, Adell L, Merdasa F et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomized multicentre study. Eur Urol 55(4): 773-780.
11. Hendricksen K, Witjes WP, Idema JG et al (2008) Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53: 984-991.
12. Kuroda M, Niijima T, Kotake T et al (2004) Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45: 600-605.
13. Hameed A, Sezian N, Thwaini A (2007) Bladder contracture: review for intravesical bacillus Calmette-Guerin complication. Can J Urol 14: 3745-3749.
14. Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169: 90-95.
15. Shelley MD, Wilt TJ, Court J et al (2004) Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93: 485-490.
16. Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67: 1216-1223.
17. Hinotsu S, Akaza H, Ohashi Y, Kotake T (1999) Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86: 1818-1826.
18. Kaasinen E, Rintala E, Hellström P et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42: 167-174.